Abstract
A total of 14 patients with platinum-resistant advanced epithelial ovarian cancer were treated with a continuous infusion of high-dose 5-fluorouracil (5-FU, 1200 mg/m2 per day) for 2 consecutive days weekly for 4 weeks and, thereafter, every 2 weeks in combination with a push injection of folinic acid (20 mg/m2) given just before 5-FU and after 24 h. No objective response was documented, and only five patients showed stable disease. The median survival was 6.5 months. There was minimal toxicity. This schedule of 5-FU in combination with folinic acid is not effective as second-line chemotherapy in advanced ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bagley CM, Young RC, Canellos GP, De Vita VT (1972) Treatment of ovarian carcinoma: possibilities for progress. N Engl J Med 287: 856
Budd GT, Fleming TR, Bukowski RM, McCracken JD, Rivkin SE, O'Bryan RM, Balcerzak SP, Macdonald JS (1987) 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group study. J Clin Oncol 5: 272
Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329: 1550
Canon J-L, Humblet Y, Symann M (1990) Resistance to cisplatin: how to deal with the problem? Eur J Cancer 26: 1
De Gramont A, Krulik M, Cady J, Lagadec B, Maisani J-E, Loiseau J-P, Grange J-D, Gonzalez-Canali G, Demuynck B, Louvet C, Seroka J, Dray C, Debray J (1988) High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24: 1499
Erlichman C, Fine S, Wong A, Elhakim T (1988) A randomized trial of 5-fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469
Louvet C, Gramont A de, Demuynck B, Varette C, Beerblock K, Bennamoun M, Krulik M (1992) Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study. Ann Oncol 3: 657
Pinedo HM, Peters GJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653
Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407
Seifert P, Baker LH, Reed ML, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36: 123
Thigpen JT, Vance RB, Khansur T (1993) Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71: 1559
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kamphuis, J.T., Huider, M.C., Ras, G.J. et al. High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer. Cancer Chemother. Pharmacol. 37, 190–192 (1995). https://doi.org/10.1007/BF00685649
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685649